Buprenorphine

"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.

Descriptor ID	D002047
MeSH Number(s)	D03.132.577.249.150 D03.605.497.150 D03.633.400.686.150 D04.615.723.795.150
Concept/Terms	Buprenorphine Buprenorphine Buprenex Buprenex Prefin Prefin Subutex Subutex Buprex Temgesic Temgésic 6029-M 6029-M 6029 M 6029M RX-6029-M RX 6029 M RX6029M Buprenorphine Hydrochloride Buprenorphine Hydrochloride Hydrochloride, Buprenorphine

Below are MeSH descriptors whose meaning is more general than "Buprenorphine".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Alkaloids [D03.132]
Opiate Alkaloids [D03.132.577]
Morphinans [D03.132.577.249]
Buprenorphine [D03.132.577.249.150]
Heterocyclic Compounds, Bridged-Ring [D03.605]
Morphinans [D03.605.497]
Buprenorphine [D03.605.497.150]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 4 or More Rings [D03.633.400]
Morphinans [D03.633.400.686]
Buprenorphine [D03.633.400.686.150]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Phenanthrenes [D04.615.723]
Morphinans [D04.615.723.795]
Buprenorphine [D04.615.723.795.150]

Below are MeSH descriptors whose meaning is related to "Buprenorphine".

Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".

Buprenorphine
Buprenorphine, Naloxone Drug Combination

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Buprenorphine" by people in this website by year, and whether "Buprenorphine" was a major or minor topic of these publications.

Bar chart showing 46 publications over 19 distinct years, with a maximum of 5 publications in 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1999	1	0	1
2003	1	0	1
2006	1	0	1
2007	4	0	4
2008	2	0	2
2009	4	0	4
2010	1	0	1
2011	4	0	4
2012	2	1	3
2013	5	0	5
2014	3	0	3
2015	1	0	1
2017	1	0	1
2020	1	2	3
2021	3	0	3
2022	1	0	1
2023	3	0	3
2024	2	0	2
2025	2	1	3

Below are the most recent publications written about "Buprenorphine" by people in Profiles.

Shastry S, Carpenter J, Krotulski A, Brent J, Wax P, Aldy K, Campleman S, Culbreth R, Falise A, Hughes A, Hendrickson RG, Amaducci A, Judge B, Meaden C, Calello DP, Buchanan J, Shulman J, Levine M, Schwarz E, Manini AF. Disparities in Treatment and Referral After an Opioid Overdose Among Emergency Department Patients. JAMA Netw Open. 2025 07 01; 8(7):e2518569.

View in: PubMed
Tata V, Varisco TJ, Rinker DV, Abughosh S, Rhodes C, Thornton JD. Concurrent Depression Management in Patients with Opioid Use Disorder Undergoing Buprenorphine Therapy: Association with Buprenorphine Discontinuation. J Dual Diagn. 2025 Apr; 21(2):142-151.

View in: PubMed
Iscoe MS, Diniz Hooper C, Levy DR, Buchanan L, Dziura J, Meeker D, Taylor RA, D'Onofrio G, Oladele C, Sarpong DF, Paek H, Wilson FP, Heagerty PJ, Delgado MK, Hoppe J, Melnick ER. Adaptive decision support for addiction treatment to implement initiation of buprenorphine for opioid use disorder in the emergency department: protocol for the ADAPT Multiphase Optimization Strategy trial. BMJ Open. 2025 Feb 20; 15(2):e098072.

View in: PubMed
Balise RR, Hu MC, Calderon AR, Odom GJ, Brandt L, Luo SX, Feaster DJ. Data cleaning and harmonization of clinical trial data: Medication-assisted treatment for opioid use disorder. PLoS One. 2024; 19(11):e0312695.

View in: PubMed
Luo SX, Feaster DJ, Liu Y, Balise RR, Hu MC, Bouzoubaa L, Odom GJ, Brandt L, Pan Y, Hser YI, VanVeldhuisen P, Castillo F, Calderon AR, Rotrosen J, Saxon AJ, Weiss RD, Wall M, Nunes EV. Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment. JAMA Psychiatry. 2024 01 01; 81(1):45-56.

View in: PubMed
Cooper RL, Edgerton RD, Watson J, Conley N, Agee WA, Wilus DM, MacMaster SA, Bell L, Patel P, Godbole A, Bass-Thomas C, Ramesh A, Tabatabai M. Meta-analysis of primary care delivered buprenorphine treatment retention outcomes. Am J Drug Alcohol Abuse. 2023 11 02; 49(6):756-765.

View in: PubMed
Brandt L, Hu MC, Liu Y, Castillo F, Odom GJ, Balise RR, Feaster DJ, Nunes EV, Luo SX. Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder. Am J Psychiatry. 2023 05 01; 180(5):386-394.

View in: PubMed
Vowles KE, Witkiewitz K, Clarke E, Schmidt Z, Borsari B, Edwards KE, Korecki JR, Moniz-Lewis DI, Bondzie JA, Mullins C, Thoreson CI, Delacruz J, Wilkins CH, Nelson S, Delventura J, Henderson R, Katz A, Hua W, Watson E, Baxley C, Canlas BR, Pendleton T, Herbst E, Batki S. Rationale and design of a multisite randomized clinical trial examining an integrated behavioral treatment for veterans with co-occurring chronic pain and opioid use disorder: The pain and opioids integrated treatment in veterans (POSITIVE) trial. Contemp Clin Trials. 2023 03; 126:107096.

View in: PubMed
Jakubowski A, Rath C, Harocopos A, Wright M, Welch A, Kattan J, Navos Behrends C, Lopez-Castro T, Fox AD. Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation. Harm Reduct J. 2022 07 10; 19(1):75.

View in: PubMed
Santiago D, Rosario Y, Melin K, Duconge J, Roman L, Gonzalez A, Venkataramanan R. Brand-to-Generic Substitution of Buprenorphine/Naloxone Sublingual Film in Puerto Rico: A Case Study. P R Health Sci J. 2021 12; 40(4):192-194.

View in: PubMed

People

Explore

Similar Concepts

Top Journals